1. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
   Tom Van Maerken et al, 2014, Cancer Letters CrossRef
2. Effect of low doses of actinomycin D on neuroblastoma cell lines
   Constanza L. Cortes et al, 2016, Molecular Cancer CrossRef
3. Intercellular extrachromosomal DNA copy-number heterogeneity drives neuroblastoma cell state diversity
   Maja C. Stöber et al, 2024, Cell Reports CrossRef
4. The MYCN Protein in Health and Disease
   María Victoria Ruiz-Pérez et al, 2017, Genes CrossRef
5. Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
   Alan Van Goethem et al, 2017, Oncotarget CrossRef
6. MYCN in Neuroblastoma: “Old Wine into New Wineskins”
   Maria Braoudaki et al, 2021, Diseases CrossRef
7. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma
   Daniela Raguer Valadão de Souza et al, 2011, Pediatric Blood & Cancer CrossRef
8. Well-Differentiated/Dedifferentiated Liposarcomas
   Sachiv Sheth et al, 2012, Pathology Case Reviews CrossRef
9. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation
   Tongsen Zheng et al, 2010, Tumor Biology CrossRef
10. Combination therapy with p53–MDM2 binding inhibitors for malignancies
    Zegao Jin et al, 2015, Medicinal Chemistry Research CrossRef
11. TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma
    John M. Yavorski et al, 2016, Cell Cycle CrossRef